Last reviewed · How we verify
rhTSH
rhTSH (recombinant human thyroid-stimulating hormone) stimulates the thyroid gland to produce and release thyroid hormones.
rhTSH (recombinant human thyroid-stimulating hormone) stimulates the thyroid gland to produce and release thyroid hormones. Used for Thyroid cancer (radioactive iodine ablation adjunct), Hypothyroidism (thyroid hormone stimulation).
At a glance
| Generic name | rhTSH |
|---|---|
| Also known as | Thyrogen - GEnzyme, Thyrogen, Recombinant human thyroid-stimulating hormone, recombinant human thyroid stimulating hormone, thyrotropin alfa |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Drug class | Recombinant hormone |
| Target | TSH receptor (TSHR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
rhTSH is a recombinant form of the pituitary hormone TSH that binds to TSH receptors on thyroid follicular cells, triggering thyroid hormone synthesis and secretion. It is used clinically to enhance radioactive iodine uptake in thyroid cancer patients and to stimulate thyroid hormone production in hypothyroid patients without requiring exogenous thyroid hormone withdrawal.
Approved indications
- Thyroid cancer (radioactive iodine ablation adjunct)
- Hypothyroidism (thyroid hormone stimulation)
Common side effects
- Headache
- Nausea
- Fatigue
- Hyperthyroidism symptoms
Key clinical trials
- ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer (NA)
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (PHASE2)
- Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma (PHASE1)
- The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer (PHASE2)
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
- Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) (PHASE2)
- Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhTSH CI brief — competitive landscape report
- rhTSH updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI